Google
CLLS — CELLECTIS SA (Healthcare >> Biotechnology)
CLLS FAQ
What is CLLS's P/E ratio?
CELLECTIS SA (CLLS) currently trades at a P/E ratio of 522.70.
What is CLLS's ROE?
CELLECTIS SA reports a Return on Equity (ROE) of -112.31%.
What is CLLS's dividend yield?
CELLECTIS SA offers a dividend yield of 0.00%.
What is CLLS's Deepscope Quality Score?
Deepscope rates CLLS's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CLLS?
Deepscope's AI Timing Score for CLLS is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CLLS belong to?
CELLECTIS SA is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 3.06
Price
-0.09
(-2.86%)
Day Change
|
|
|---|
CLLS, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 73 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.06 |
| PBV / Sector |
5.14 / 4.63
|
| Earning Per Share | -0.67 |
| PE / Sector |
522.70 / 17.43
|
| PEG or PE/Growth / Sector |
-53.67 / 0.53
|
| Average 1M Daily Value |
0.15 M
GREAT
|
| Average 1W Daily Value |
0.21 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
43% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:29 |
| Symbol | CLLS |
| Name | CELLECTIS SA |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 72.61 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 307.87 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 8, rue de la Croix Jarry, Paris, France, 75013
Phone: 33 1 81 69 16 00
Website: https://www.cellectis.com
Employees: 224
Sector: Healthcare >> Biotechnology
Description: Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
